Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
Results from a new study showed that end-of-year drug approvals by the FDA are linked to more hospitalizations, life-threatening events and deaths, a rate about twice as high as medicines approved earlier in the year. More news on: ProShares Trust - ProShares Ultra Nasdaq Biotechnology,...
A good run The portfolio was up 6.06% in Q4 and 26.79% for 2019. The four-year gain has been 62.40%. We've had several good runs since I began investing in 1982. At some point, we'll have a bear market. Don't get complacent. During 2019, we began taking monthly distributions from my IRA. I...
Reuters reports that pharmaceutical companies, including Pfizer (NYSE: PFE ), GlaxoSmithKline (NYSE: GSK ) and Sanofi (NASDAQ: SNY ), are planning to raise prices on more than 200 medicines in the U.S. tomorrow. More news on: Pfizer Inc., GlaxoSmithKline plc, Sanofi, Healthcare stocks ne...
Deals and Financings Geneseeq, a Nanjing-Toronto company that offers genetic sequencing tests for cancer, completed a $114 million Series D financing led by China Reform Holdings Corporation (see story ). Geneseeq uses next-gen sequencing to provide decision-making tools for physicians. The...
Roche ( RHHBY ) has been quite busy in 2019 and it is apparent that it is making a hard push towards building a pipeline of gene therapies. This involves two major deals this year dealing specifically with gene therapy companies. Both of these were large ones, and it shows the commitment of Ro...
The FDA Breakthrough Therapy Designation (BTD) was an offshoot of the Food and Drug Administration Safety and Innovation Act (FDASIA) that was signed on July 9, 2012 , that called for a new designation to be created. Since 2012, only 147 drugs have been approved having this designation, which...
Sarepta Therapeutics, Inc. ( SRPT ) is having another strong day of buying as the company's latest licensing agreement builds an already impressive cash hoard for the company along with other, less-obvious benefits. This follows quickly on the heels of another monumental day for the company as...
Investing in the best growth stocks can generate superior returns over the long term. On the other hand, growth stocks are also particularly volatile and risky. The key, like usually happens, is separating the fundamentally sound companies from the ones with mediocre fundamentals. The follow...
Merger activity increased, with nine new deals announced and six deals closing. Deal Statistics New Deals The acquisition of LogMeIn (LOGM) by Francisco Partners for $4.3 billion or $86.05 per share in cash. We added LOGM as a potential deal to the Deals in the Works section on Dece...
Sarepta Therapeutics (NASDAQ: SRPT ) is up 13% premarket on entering into a licensing agreement with Roche ( OTCQX:RHHBY ), providing latter an exclusive commercial rights to SRP-9001, an investigational gene therapy for Duchenne muscular dystrophy (DMD), outside the ...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Wednesday, HOOKIPA Pharma Inc (NASDAQ:HOOK) received clearance from the FDA for its Investigational New Drug (IND) application for H...
– Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeks – – The twice-yearly, 10-minute SC injection has th...
Monday, Roche Holdings AG (OTC:RHHBY) announced topline data from Phase 3 STARGLO study of Columvi (glofitamab) in combination ...